ALIM - アリメラ・サイエンシ―ズ (Alimera Sciences Inc.) アリメラ・サイエンシ―ズ

 ALIMのチャート


 ALIMの企業情報

symbol ALIM
会社名 Alimera Sciences Inc. (アリメラ・サイエンシ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アリメラ・サイエンシーズ(Alimera Sciences Inc.)は処方眼科医薬品の研究・開発・商業化を専門に扱うバイオ医薬品企業。同社は眼底や網膜に影響を与える疾患を中心に取り扱う。同社の製品候補「ILUVIEN」は非外科的治療手順であり、25ゲージ針付きのデバイスを採用し、傷のセルフシールを可能にする。また、「ILUVIEN」はドライ型加齢黄斑変性症(AMD)、ウェット型AMD及び網膜静脈閉塞症(RVO)を治療するために3つの第2相臨床試験で研究されている。「ILUVIEN」は硝子体内インプラントであり、非独占の副腎皮質ステロイドであるフルオシノロンアセトニド(FAc)の持続的なサブマイクログラムレベルを提供することにより、糖尿病性黄斑浮腫(DME)に関連する視力障害の治療で最大36ヶ月の治療効果を提供する。   アリメラ・サイエンシ―ズは米国のバイオ医薬品メ―カ―。眼科薬の研究、開発、商業化に従事。主に、眼球の裏側や網膜に影響を及ぼす疾患に焦点を当てている。慢性糖尿病性黄斑浮腫に関連した視力障害治療薬「イルビエン」は、英国、オ―ストリア、ポルトガル、フランス、ドイツ、スペインで販売承認を受けている。本社はジョ―ジア州。   
本社所在地 6120 Windward Parkway Suite 290 Alpharetta GA 30005 USA
代表者氏名 Richard S. Eiswirth リチャードエスワース
代表者役職名 President Chief Financial Officer
電話番号 +1 678-990-5740
設立年月日 37773
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 126人
url www.alimerasciences.com
nasdaq_url https://www.nasdaq.com/symbol/alim
adr_tso
EBITDA EBITDA(百万ドル) -14.46000
終値(lastsale) 0.931
時価総額(marketcap) 65205760.641
時価総額 時価総額(百万ドル) 66.07424
売上高 売上高(百万ドル) 39.64500
企業価値(EV) 企業価値(EV)(百万ドル) 156.19224
当期純利益 当期純利益(百万ドル) -24.19300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alimera Sciences Inc revenues increased 22% to $20.7M. Net loss increased 23% to $11.7M. Revenues reflect United States segment increase of 20% to $15M International segment increase of 28% to $5.7M. Higher net loss reflects United States segment loss increase of 21% to $2.7M International segment loss increase of 27% to $1.2M.

 ALIMのテクニカル分析


 ALIMのニュース

   Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference  2021/01/05 13:00:00 GlobeNewswire
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of…
   Alimera Sciences Announces Third Quarter 2020 Financial Results  2020/10/28 20:05:00 GlobeNewswire
Rebound Continues from COVID Challenges
   Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update  2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
   Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update  2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
   Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates  2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Alimera Sciences Announces Third Quarter 2020 Financial Results  2020/10/28 20:05:00 GlobeNewswire
Rebound Continues from COVID Challenges
   Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update  2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
   Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update  2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
   Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates  2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Alimera Sciences Refinances Debt Facility With Solar Capital  2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .
   Alimera Sciences Announces Third Quarter 2020 Financial Results  2020/10/28 20:05:00 GlobeNewswire
Rebound Continues from COVID Challenges
   Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update  2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
   Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update  2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
   Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates  2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Alimera Sciences Refinances Debt Facility With Solar Capital  2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .

 関連キーワード  (医薬品 米国株 アリメラ・サイエンシ―ズ ALIM Alimera Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)